Melinda Klug
Acute Care · Show Low, AZNPI 1679998744
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,879 of the $3,970 with a category attached, or 72.5%. Inspire Medical Systems, Inc. accounts for 69.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $2,350 and has fallen 57.1% since, to $1,007 in 2025.
Across 90 payments — averaging $44.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- Actelion Pharmaceuticals US, Inc.$198
- Jazz Pharmaceuticals Inc.$188
- GSK$98
- Harmony Biosciences LLC$97
- AstraZeneca$82
- plus $569 from 18 others
What the payments were for
- Consulting fees$1504%
- Travel & lodging$94124%
- Food & beverage$2,87973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 52 | $2,738 |
| Actelion Pharmaceuticals US, Inc. | 3 | $198 |
| Jazz Pharmaceuticals Inc. | 2 | $188 |
| GSK | 4 | $98 |
| Harmony Biosciences LLC | 4 | $97 |
| AstraZeneca | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $71 |
| Bayer | 1 | $55 |
| Sanofi | 1 | $37 |
| Viatris Specialty LLC | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Verona Pharma, Inc. | 1 | $25 |
| Amgen | 1 | $25 |
| Grifols USA, LLC | 1 | $25 |
| ZOLL Respicardia, Inc. | 1 | $24 |
| Pulmonx Corporation | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Resmed Corp | 1 | $20 |
| Itamar Medical Inc | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,970 in reported general payments places this provider in the 85th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $142,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $98,167 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $29,559 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,336 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,597 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $3,469 |
| Ventolin HfaAlbuterol Sulfate | 30 | $3,315 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,907 |
| Fluticasone Propionate | 63 | $1,237 |
| Montelukast Sodium | 71 | $587 |
| Azelastine Hcl | 12 | $441 |
| Eszopiclone | 15 | $227 |
| Zolpidem Tartrate | 21 | $102 |
| Prednisone | 17 | $65 |
| Modafinil | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $22 | $142,96211 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $98 | $127,726174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 482 acute care providers in Arizona.
Other acute care in Show Low
- Nicole CiffoneTucson$162K
- Kim KrmpoticPhoenix$79K
- Stephanie WilsonScottsdale$37K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Seania BristolMesa$11K
- Brooke GambinoPhoenix$11K
- Stephanie TironeGlendale$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.